☆ 4.7 Review

Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases

JOURNAL OF MEDICAL VIROLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Cell Biology

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Shuai Xia et al.

CELL RESEARCH (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas et al.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

NATURE (2022)

添加到收藏夹

Editorial Material Immunology

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern

Shan Su et al.

Summary: The simultaneous presence of SARS-CoV-2 and MERS-CoV raises concerns about the potential emergence of new beta-coronavirus strains with high transmissibility similar to SARS-CoV-2 and high mortality rates similar to MERS-CoV. Therefore, there is an urgent need to develop pan-beta-CoV vaccines capable of targeting not only current variants of concern, but also potential future coronaviruses resembling SARS-CoV-3 or MERSCoV-2.

TRENDS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection

Zai Wang et al.

Summary: This study demonstrates the presence of antibody-mediated enhancement (ADE) in SARS-CoV-2, which requires ACE2 as a secondary receptor. Additionally, the ACE2-binding affinity of virus strains may affect the extent of ADE.

ISCIENCE (2022)

添加到收藏夹

News Item Infectious Diseases

Research in brief

Sharmila Devi

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle

Kailu Yang et al.

Summary: Variants of SARS-CoV-2 challenge current COVID-19 vaccines and antibody therapies. Mutations in the viral spike glycoprotein impact the fusion process, but do not alter the overall structure of the viral bundle. Targeting the interface between HR1 and HR2 could be an effective strategy for developing antiviral inhibitors against all known SARS-CoV-2 variants.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

添加到收藏夹

Article Virology

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern

Lixiao Xing et al.

Summary: The study developed a novel fusion inhibitor-based recombinant protein that showed potent inhibition against SARS-CoV-2 and its variants, including Omicron and Delta.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Virology

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern

Qiaoshuai Lan et al.

Summary: Cholesterol-conjugated, peptide-based pan-coronavirus fusion inhibitors have been shown to effectively inhibit human coronavirus infection. A newly developed lipopeptide drug called EK1-C16, modified with palmitic acid (C16), has demonstrated potent inhibition against SARS-CoV-2 and its variants, as well as other human CoVs and bat SARS-related CoVs. This suggests that EK1-C16 could be a promising candidate for the prevention and treatment of current and future coronaviruses.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Virology

A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life

Qianyu Duan et al.

Summary: This study developed a new antiviral drug, FL-EK1, which effectively inhibits the infection of SARS-CoV-2, its variants, and HCoV-OC43. It also provides protection against the SARS-CoV-2 Delta variant and HCoV-OC43 in mice. Importantly, FL-EK1 has a longer half-life compared to the previous drug EK1, making it a promising candidate for the development of a long-acting antiviral drug against current and future SARS-CoV-2 variants and other HCoVs.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Virology

The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants

Jing Pu et al.

Summary: In recent years, viral infections have posed serious threats to human health, particularly the global spread of COVID-19 caused by SARS-CoV-2. This study introduces a series of small-molecule compounds effective against various human coronaviruses, including SARS-CoV-2 and its variants of concern. The compounds show potential antiviral activity against different classes of enveloped viruses and may act through multiple mechanisms, making them promising drug candidates for SARS-CoV-2 and other enveloped viruses.

VIRUSES-BASEL (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Recent advances in developing small-molecule inhibitors against SARS-CoV-2

Rong Xiang et al.

Summary: The COVID-19 pandemic has caused chaos worldwide, with vaccines in distribution but treatment methods lagging behind. Researchers are working hard to understand the virus and develop effective treatments.

ACTA PHARMACEUTICA SINICA B (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases

Jie Zhou et al.

Summary: The development of broad-spectrum antivirals against human coronaviruses is crucial for combating the COVID-19 pandemic and future outbreaks. A new lipopeptide drug, EKL1C, has potent inhibitory activity against SARS-CoV-2 and its variants, as well as other coronaviruses. It exhibits better stability and metabolic stability compared to previous drugs, making it a potential candidate for COVID-19 and other coronavirus diseases.

ACTA PHARMACEUTICA SINICA B (2022)

添加到收藏夹

Article Biology

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit

Nicholas K. Hurlburt et al.

Summary: Structural and functional characterisation of antibody CV3-25 reveals its wide neutralisation spectrum against multiple SARS-CoV2 variants, including the Alpha, Delta, Gamma, and Omicron variants, as well as a SARS-CoV-like bat coronavirus. This study highlights the importance of CV3-25 as a potential therapeutic and vaccine candidate for broad protection against coronaviruses.

COMMUNICATIONS BIOLOGY (2022)

添加到收藏夹

Review Microbiology

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant

Hao Zhou et al.

Summary: The SARS-CoV-2 virus is continuously evolving and mutating, with the emergence of the highly mutated and transmissible Omicron variant. This variant evades protection from vaccines and antibody-based therapies, but is sensitive to certain antiviral drugs. Understanding the virology and immune mechanisms of the Omicron variant is crucial for developing effective vaccines and treatments.

CLINICAL MICROBIOLOGY REVIEWS (2022)

添加到收藏夹

Letter Virology

Neutralization of distinct Omicron sublineages by longitudinal vaccination sera

Xun Wang et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Microbiology

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern

Katharina S. Schmitz et al.

Summary: SARS-CoV-2 continues to spread globally, with new variants that evade immunity generated by vaccines and previous strains. Fusion-inhibitory peptides may provide an intervention strategy that is not affected by viral evolution.

MBIO (2022)

添加到收藏夹

Article Microbiology

Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2

Xiaoyu Sun et al.

Summary: The antibody 76E1 isolated from a COVID-19 convalescent patient shows broad range neutralizing activity against multiple coronaviruses, including SARS-CoV-2 variants. It targets a unique epitope within the spike protein, blocking viral entry and providing cross-protection in both prophylactic and therapeutic animal models.

NATURE MICROBIOLOGY (2022)

添加到收藏夹

Article Cell Biology

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein

Songyi Xue et al.

Summary: A compound called S-20-1 has been identified with potent membrane fusion inhibitory activity against SARS-CoV-2 and its variants. It can effectively inhibit infection by targeting two sites in the S protein and has favorable oral bioavailability. S-20-1 shows high resistance to proteolytic degradation and broad-spectrum anti-coronavirus activity.

CELL DISCOVERY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages

Shuai Xia et al.

Summary: The Omicron variant and its sublineages exhibit increased transmissibility and immune escape, leading to numerous infections and breakthrough cases.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Sho Iketani et al.

Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.

NATURE (2022)

添加到收藏夹

Review Microbiology

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu et al.

Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.

NATURE REVIEWS MICROBIOLOGY (2021)

添加到收藏夹

Article Cell Biology

Pan-coronavirus fusion inhibitors as the hope for today and tomorrow

Xinling Wang et al.

PROTEIN & CELL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets

Rory D. de Vries et al.

Summary: The lipopeptide fusion inhibitors designed effectively blocked the critical first step of SARS-CoV-2 infection. Daily intranasal administration to ferrets prevented transmission completely, showcasing potential as safe and effective prophylaxis for reducing SARS-CoV-2 transmission.

SCIENCE (2021)

添加到收藏夹

Review Cell & Tissue Engineering

Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks

Miao Cao et al.

STEM CELL REPORTS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Antivirals with common targets against highly pathogenic viruses

Lu Lu et al.

Summary: Throughout history, emerging viruses have constantly appeared and have resulted in millions of human deaths. Climate change and globalization have now created favorable conditions for viral transmission. Thus, the development of effective antivirals, particularly those targeting conserved proteins in multiple unrelated viruses, is urgently needed to combat future emerging and re-emerging viruses.

CELL (2021)

添加到收藏夹

Article Virology

Exploring the efficacy of naturally occurring biflavone based antioxidants towards the inhibition of the SARS-CoV-2 spike glycoprotein mediated membrane fusion

Samiran Mondal et al.

Summary: Natural biflavones like hinokiflavone and robustaflavone show potential as inhibitors for SARS-CoV-2 viral entry mediated by the S protein, effectively blocking the virus-target cell membrane fusion process.

VIROLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Chunyan Wang et al.

Summary: Research has isolated two human monoclonal antibodies from immunized humanized mice that display cross-reactivity against various beta coronaviruses, targeting the stem helix in the spike S2 fusion subunit. These antibodies block MERS-CoV infection in cells and provide protection against lethal MERS-CoV challenge in mice, showcasing their potential for developing broad-spectrum antibodies. Despite exhibiting cross-reactivity, the antibodies only neutralize MERS-CoV due to subtle epitope differences in the spike S2 fusion subunit.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

添加到收藏夹

Review Microbiology

SARS-CoV-2 variants, spike mutations and immune escape

William T. Harvey et al.

Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.

NATURE REVIEWS MICROBIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Broad betacoronavirus neutralization by a stem helix-specific human antibody

Dora Pinto et al.

Summary: The study identified five monoclonal antibodies from COVID-19 convalescent individuals that cross-react with multiple betacoronavirus spike glycoproteins, with one antibody (S2P6) showing broad neutralization of viruses from three different subgenera. This antibody reduced viral burden in hamsters challenged with SARS-CoV-2 by inhibiting membrane fusion, providing a framework for the design of pan-betacoronavirus vaccines for broad protection.

SCIENCE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Virtual Screening of Phytochemicals by Targeting HR1 Domain of SARS-CoV-2 S Protein: Molecular Docking, Molecular Dynamics Simulations, and DFT Studies

Arshia Majeed et al.

Summary: This study utilized computer-aided drug discovery methods to explore the potential of different phytochemicals as candidates against COVID-19, ultimately identifying 5 phytochemicals as novel and potent inhibitors of the HR1 domain in the SARS-CoV-2 spike protein.

BIOMED RESEARCH INTERNATIONAL (2021)

添加到收藏夹

Article Health Care Sciences & Services

MERS-CoV in the COVID-19 era: update from Saudi Arabia, 2019-2020

Anas Khan et al.

Summary: The study provides an update on the epidemiology of MERS-CoV in Saudi Arabia from January 2019 to October 2020, revealing that older age and comorbidities are associated with higher mortality, while exposure to camels is linked to lower mortality. Additionally, healthcare providers had a lower mortality rate compared to non-healthcare providers.

EASTERN MEDITERRANEAN HEALTH JOURNAL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

Shuai Xia et al.

Summary: The COVID-19 pandemic and its variants pose a global threat to public health and economy. EK1 and EK1C4 demonstrate potent antiviral activity against SARS-CoV-2 infection, with potential for further clinical development.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion

Chan Yang et al.

Summary: The study found that Itraconazole and Estradiol benzoate can inhibit viral entry by targeting the six-helix fusion core of SARS-CoV-2 S protein, presenting them as novel potential therapeutic remedies for COVID-19 treatment. Further research also showed that Itraconazole has broad-spectrum activity targeting 6-HB in the S2 subunit of SARS-CoV and MERS-CoV S protein, suggesting its potential as a pan-coronavirus fusion inhibitor.

ADVANCED THERAPEUTICS (2021)

添加到收藏夹

Letter Immunology

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Shuai Xia et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

添加到收藏夹

Article Cell Biology

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Shuai Xia et al.

CELL RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins

Kangpeng Xiao et al.

NATURE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

Fei Yu et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Shuai Xia et al.

SCIENCE ADVANCES (2019)

添加到收藏夹

Article Virology

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD

Cong Wang et al.

VIRUSES-BASEL (2019)

添加到收藏夹

Article Microbiology

IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies

Wenwen Bi et al.

PLOS PATHOGENS (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

MERS-CoV spike protein: a key target for antivirals

Lanying Du et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2017)

添加到收藏夹

Article Virology

Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides

Jung-Eun Park et al.

VIROLOGY (2017)

添加到收藏夹

Article Immunology

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

Rudragouda Channappanavar et al.

JOURNAL OF INFECTIOUS DISEASES (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

Lu Lu et al.

NATURE COMMUNICATIONS (2014)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents

Ricardo P. Garay et al.

EXPERT OPINION ON DRUG DELIVERY (2012)

添加到收藏夹

Article Immunology

Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial

Dominique Salmon-Ceron et al.

AIDS (2010)

添加到收藏夹

Article Medicine, General & Internal

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

SW Liu et al.

LANCET (2004)

添加到收藏夹

Article Multidisciplinary Sciences

Protein design of an HIV-1 entry inhibitor

MJ Root et al.

SCIENCE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.